Breast Cancer

Studies to be presented at the 2026 ASCO Annual Meeting examine GLP-1 receptor agonists in relation to cancer progression, survival, and immune-related adverse events.

Study findings suggest biologic aging and neighborhood deprivation may shape cognitive benefits from exercise after breast cancer.

The FDA approved T-DXd for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, showing improved pCR and IDFS rates.

Experts warn of "molecular anxiety" and financial toxicity as ctDNA testing enters early-stage breast cancer surveillance.

Learn about the FDA approval of vepdegestrant (Veppanu), the first PROTAC for ESR1-mutated breast cancer, including nursing priorities and side effects.

FDA approved Veppanu for ER+, HER2- ESR1-mutated breast cancer after endocrine therapy, improving PFS to 5 months vs 2.1 and reducing progression risk by 43%.

Paget disease of the breast: key signs, diagnosis, and treatment strategies oncology nurses should know to support early detection and patient care.

The OPTIMAL trial shows oral DHP107 matches IV paclitaxel efficacy in HER2-negative metastatic breast cancer with lower rates of neuropathy.

The NCCN has added sacituzumab govitecan with pembrolizumab as a category 1 preferred regimen for patients with PD-L1–postive TNBC.

Radiation-induced heart damage in breast cancer is a growing clinical concern, yet biomarkers and preventive therapies remain lacking.

A multidisciplinary approach to care is key when addressing sexual health concerns among breast cancer survivors.

Mark S. Lin, MSN, FNP-BC, highlighted nursing considerations for breast reconstruction surgery in breast cancer.

Don S. Dizon, MD, FACP, FASCO, shared insights on what pregnancy looks like with a breast cancer diagnosis and what those considering pregnancy should know.

Findings from real-world community clinics show favorable efficacy of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer.

Patricia Jakel, MN, RN, AOCN, shares how personal and professional experience impact her view on testing even beyond what is recommended.

What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast cancer?

Data show that sentinel lymph node biopsy is becoming less routine for older women with breast early stage HR-positive, HER2-negative breast cancer.

A significant portion of patients with locally advanced breast cancer receiving ultra-hypofractionation radiotherapy responded to treatment.

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04.

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk severe or fatal toxicities.

Dato-DXd has been given priority review for the treatment of patients with unresectable/metastatic triple-negative breast cancer.

Plus, a phase 1 breast cancer vaccine, updated NCCN guidelines, and a combination with standard-of-care potential in triple-negative breast cancer.

Destiny-Breast09 PROs demonstrated higher quality of life and fewer gastrointestinal symptoms in patients with HER2-positive advanced breast cancer.

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025.